Literature DB >> 12357302

The effects of food on the pharmacokinetic profile of oral vinorelbine.

Roland Bugat1, Philippe Variol, Henri Roché, Pierre Fumoleau, Gilles Robinet, Isabelle Senac.   

Abstract

The effects of food on the pharmacokinetics and safety profile of a soft-gel capsule formulation of vinorelbine (Navelbine Oral) were evaluated in fed and fasted patients with solid tumours or lymphomas. A group of 18 patients (12 planned) were entered into a multicentre phase I pharmacokinetic study following a crossover design with a 1-week wash-out period. Patients received the first dose of 80 mg/m(2) oral vinorelbine either after fasting or after ingestion of a standard continental breakfast. The second dose of 80 mg/m(2) was administered 1 week later in the alternate feeding condition to the first dose. Of the 18 patients, 13 were eligible for pharmacokinetic evaluation. The mean time to maximum concentration (T(max)) was shorter in fasted patients (1.63+/-0.98 h in blood, 1.67+/-0.96 h in plasma) than in fed patients (2.48+/-1.40 h in blood, 2.56+/-1.65 h in plasma) but these differences are not likely to modify the safety and/or efficacy of oral vinorelbine. Values for C(max) and AUC were similar in fed and fasted patients and no significant differences were observed. The safety profile of oral vinorelbine observed in this limited number of patients appears to be comparable to that usually reported for vinorelbine, the main toxicity being neutropenia. Only one episode of febrile neutropenia was reported. The main nonhaematological toxicities encountered were gastrointestinal, consisting of nausea, vomiting, diarrhoea and constipation. A tendency for a lower incidence of vomiting was suggested when oral vinorelbine was administered after a standard breakfast. Based on this study, the administration of oral vinorelbine to fasted patients is not mandatory since administration after a standard breakfast does not lead to differences in body exposure to the drug. As the comfort of patients may be improved when the treatment is administered after a light meal, this procedure can be recommended in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12357302     DOI: 10.1007/s00280-002-0475-x

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  6 in total

1.  Inoperable stage III non-small cell lung cancer: Current treatment and role of vinorelbine.

Authors:  Mariano Provencio; Dolores Isla; Antonio Sánchez; Blanca Cantos
Journal:  J Thorac Dis       Date:  2011-09       Impact factor: 2.895

2.  Cisplatin plus oral vinorelbine as first-line treatment for advanced non-small-cell lung cancer: a prospective study confirming that the day-8 hemogram is unnecessary.

Authors:  M Provencio; A Sánchez; A Artal; J M Sánchez Torres; Ramón García Gómez; Manuel Constenla; J de Castro; M Dómine; N Viñolas; A Sánchez; F J Pérez
Journal:  Clin Transl Oncol       Date:  2013-01-29       Impact factor: 3.405

Review 3.  Oral vinorelbine in the treatment of non-small cell lung cancer: rationale and implications for patient management.

Authors:  Richard J Gralla; Ulrich Gatzemeier; Vittorio Gebbia; Rudolf Huber; Mary O'Brien; Christian Puozzo
Journal:  Drugs       Date:  2007       Impact factor: 9.546

4.  A randomised, multicentre open-label phase II study to evaluate the efficacy, tolerability and pharmacokinetics of oral vinorelbine plus cisplatin versus intravenous vinorelbine plus cisplatin in Chinese patients with chemotherapy-naive unresectable or metastatic non-small cell lung cancer.

Authors:  Yunpeng Yang; Jianhua Chang; Cheng Huang; Yiping Zhang; Jie Wang; Yongqian Shu; Jean Philippe Burillon; Marcello Riggi; Aurélie Petain; Pierre Ferre; Ying Liang; Li Zhang
Journal:  J Thorac Dis       Date:  2019-08       Impact factor: 2.895

5.  Acceptance of oral chemotherapy in breast cancer patients - a survey study.

Authors:  Sarah Schott; Andreas Schneeweiss; Judith Reinhardt; Thomas Bruckner; Christoph Domschke; Christof Sohn; Michael H Eichbaum
Journal:  BMC Cancer       Date:  2011-04-12       Impact factor: 4.430

6.  Effect of ethnicity on vinorelbine pharmacokinetics: a population pharmacokinetics analysis.

Authors:  Aurélie Pétain; Dafang Zhong; Xiaoyan Chen; Zhang Li; Shao Zhimin; Jiang Zefei; Grégoire Zorza; Pierre Ferré
Journal:  Cancer Chemother Pharmacol       Date:  2019-05-27       Impact factor: 3.333

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.